Convenient one tablet, once-a-day dosing

Dosing to fit your patient's routine1

Continue IMBRUVICA® treatment until disease progression or unacceptable toxicity.

Dosing to fit your patient's routine1

  • May be coadministered with proton pump inhibitors2,3
  • No dose adjustments required with acid-reducing agents2,3
  • Modify dose or avoid IMBRUVICA® use with CYP3A inhibitors and avoid coadministration with strong CYP3A inducers
  • Flexibility to take at home

For more customized patient management, IMBRUVICA® for WM can be dosed as a single 420-mg tablet or three 140-mg capsules1

*Agents administered in combination with IMBRUVICA® require infusion. When administering IMBRUVICA® in combination with rituximab or obinutuzumab, consider administering IMBRUVICA® prior to rituximab or obinutuzumab when given on the same day.

  • Administer IMBRUVICA® at approximately the same time each day with a glass of water
  • Swallow tablets or capsule whole. Do not open, break, or chew the capsules. Do not cut, crush, or chew the tablets
  • If a dose of IMBRUVICA® is not taken at the scheduled time, it can be taken as soon as possible on the same day with a return to the normal schedule the following day. Do not take extra doses of IMBRUVICA® to make up for the missed dose

Once-daily dosing is necessary to ensure inhibition of BTK enzymatic activity1

IMBRUVICA® occupancy at the  BTK active site was observed for up to 24 hours with once-daily dosing^1IMBRUVICA® occupancy at the  BTK active site was observed for up to 24 hours with once-daily dosing^1

BTK=Bruton’s tyrosine kinase, WM=Waldenström's Macroglobulinemia

References: 1IMBRUVICA® (ibrutinib) Prescribing Information. 2de Jong J, Haddish-Berhane N, Hellemans P, Jiao J, Sukbuntherng J, Ouellet D. The pH-altering agency omerprazole affects rate but not the extent of ibrutinib exposure. Cancer Chemoth Pharm. 2018;82(2):299-308. 3Marostica E, Sukbuntherng J, Loury D, et al. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemoth Pharm. 2015;75(1):111-121.